
First in market in Europe
Willem 2.0 AI-ECG for the early detection of cardiac diseases
Willem is now CE-marked to help physicians identify patients suggestive of heart failure and ATTR cardiac amyloidosis (ATTR-CM), alongside 29 cardiac patterns.
What's new in Willem 2.0
One ECG. Far more answers.
From the same routine recording, Willem now helps identify patients suggestive of two cardiac diseases, alongside 29 cardiac patterns.
Two diseases that often go unnoticed, now detected by Willem 2.0
Some patients wait years for a diagnosis. From a standard 12-lead resting ECG, Willem detects AI-ECG digital biomarkers, signals the human eye can't see, to help shorten that wait.

Heart Failure
Spot it sooner, with reduced or preserved ejection fraction. Early symptoms are non-specific, so heart failure can stay undetected for years.
of cases may remain undetected1
People living with heart failure worldwide2
of patients identified as Highly Suggestive are confirmed to have heart failure3
ATTR Cardiac Amyloidosis
Reach patients before years of misdiagnosis. Its symptoms mimic more common conditions., so patients often see several specialists before reaching a diagnosis.
of patients initially misdiagnosed5
before a definitive diagnosis6
of patients identified as Highly Suggestive are confirmed to have ATTR-CM3
29 cardiac patterns
on any ECG device.
From a 10-second resting ECG to 14 days of continuous monitoring, one AI platform analyses every recording.




Atrial fibrillation / Flutter
Tachycardia
Ventricular Ectopy
Atrial Ectopy
Conduction and Pauses
Sinus Rhythm
Device-agnostic.
Built to fit your workflow.
Willem works with the ECGs you already record and sends the results back to the systems you already use.
In your workflow
Record an ECG
Any ECG from your hospital or clinic: from a 10-second resting ECG to 14 days of monitoring.
Behind the scenes
Connect via API
ECGs are sent securely to Willem through an API, in standard formats.
Behind the scenes
Analyse with Willem
Every recording is analysed for 29 cardiac patterns, heart failure and ATTR-CM.
In your workflow
Get results your way
Results appear in your existing systems, ready for the physician’s review and clinical decision.
Certified, secure and ready for clinical use
A Class IIa medical device under EU MDR, built on certified quality, security and data privacy frameworks.
Class IIa Medical Device
Certified under Regulation (EU) 2017/745 (EU MDR) for heart failure, ATTR cardiac amyloidosis and 29 cardiac patterns, for use by qualified healthcare professionals.

ISO Certified
Certified for information security, privacy, quality, AI management and anti-bribery.

GDPR compliant
Meets the EU General Data Protection Regulation and the Spanish LOPD-GDD to ensure the lawful, secure processing of personal data.

Spanish National Security Scheme
ENS certified (High category) for multi-layered security and compliance with national cybersecurity regulations.

HDS
Certified for health data hosting in France, with all data hosted within the EEA.

DTAC*
Meets the NHS Digital Technology Assessment Criteria for quality, safety, interoperability and clinical effectiveness.
Peer-reviewed evidence
Published in Heart Rhythm

Improving Transthyretin cardiac amyloidosis detection from ECGs through Willem AI platform.

Accuracy that makes every referral count
Validated in real-world clinical data, across different sites and populations
ATTR-CM
patients across Europe and the US
Highly Suggestive results confirmed as ATTR-CM
Non-Suggestive results confirmed negative
Heart Failure
patients across Europe and the US
Highly Suggestive results confirmed as heart failure
Where Willem 2.0 makes a difference.
Wherever an ECG is recorded, Willem adds value: from primary care to cardiology and clinical research.



Hospitals and clinicians
From primary care to cardiology
- Support for routine ECG reads where cardiology isn’t on site
- Triage of resting ECGs and long-term recordings (Holter, patches, ICMs), so the most relevant cases are reviewed first
- Earlier, better-targeted referrals for Heart Failure and ATTR-CM

Technology partners
ECG devices, platforms and AI
- Embedded in ECG devices (carts, Holters, patches, monitors), so every recording gets AI-ECG analysis
- Available through clinical AI platforms, deployed within existing hospital workflows
- Hardware agnostic and already CE-marked under EU-MDR for heart failure and ATTR-CM

Pharma and clinical research
Find and follow the right patients
- Identify potentially eligible patients in existing ECG databases
- Reach under-diagnosed populations, such as ATTR-CM and heart failure
- Standardized, centralized ECG analysis across sites, countries and devices


The data behind Willem
patients in Idoven's ECG database, behind every model Willem runs.
Built on real-world data, with clinicians.
clinical partners worldwide
years of cardiology expertise
publications in high-impact journals
*INTENDED USE STATEMENT FROM THE WILLEM IFU": Willem interpretation results are not intended to be the sole means of diagnosis or replace traditional methods of treatment. It is offered on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Please see Instructions of use for extended information about the product.





.png)
.png)
.png)




